Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration

Author:
  • AGAge-Related Eye Disease Study 2 Research Group
    Age-Related Eye Disease Study 2 Research Group

Top Cited Papers
Open Access
Abstract
Age-related macular degeneration (AMD), the leading cause of blindness in the developed world, accounts for more than 50% of all blindness in the United States.1 In 2004, it was estimated that 8 million individuals had intermediate AMD, defined as bilateral drusen, and approximately 2 million had advanced AMD, either neovascular AMD or geographic atrophy.2 Although intraocular drugs that inhibit vascular endothelial growth factor are currently available for treatment of neovascular AMD,3 no effective therapies are proven for atrophic AMD. Without more effective ways of slowing progression, the number of persons with advanced AMD is expected to double over the next 20 years, resulting in increasing socioeconomic burden.2

This publication has 19 references indexed in Scilit: